Genmab A (GMAB) Invested Capital (2019 - 2026)

Genmab A's (GMAB) quarterly Invested Capital came in at $5.3 billion in Q4 2025, up 37571.43% on a QoQ basis from $14.0 million in Q1 2025.

Genmab A (GMAB) Invested Capital (2019 - 2026) Analysis & Trends

Genmab A (GMAB) has 3 years of Invested Capital data on file, last reported at $5.3 billion in Q4 2025.

Quarterly Invested Capital changed N/A year-over-year to $5.3 billion in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $5.3 billion (up 37571.43% YoY) and the FY2025 annual result came in at $5.3 billion, changed N/A from the prior year.
Invested Capital advanced to $5.3 billion in Q4 2025, from $14.0 million in the prior quarter.
In the past five years, Invested Capital ranged from a high of $5.3 billion in Q4 2025 to a low of $14.0 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	190.90 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	2.57 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	380.00 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Genmab A	2.05 Bn	548.77 Mn	1.07 Bn	5.14 Bn

Download Data